Zentalis Pharmaceuticals
ZNTL
ZNTL
136 hedge funds and large institutions have $261M invested in Zentalis Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 45 increasing their positions, 40 reducing their positions, and 35 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less ownership
Funds ownership: →
17% less capital invested
Capital invested by funds: $314M → $261M (-$53.1M)
18% less call options, than puts
Call options by funds: $352K | Put options by funds: $431K
26% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 35
Holders
136
Holding in Top 10
3
Calls
$352K
Puts
$431K
Top Buyers
| 1 | +$3.56M | |
| 2 | +$3.54M | |
| 3 | +$3.5M | |
| 4 |
D.E. Shaw & Co
New York
|
+$3.27M |
| 5 |
Millennium Management
New York
|
+$1.82M |
Top Sellers
| 1 | -$13.3M | |
| 2 | -$6.65M | |
| 3 | -$6.57M | |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$5.42M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.83M |